
News from MedCity News
If you want to know if MedCity News is credible or reliable, look no further. We rank MedCity News as High factuality. Find out more about our methodology here.
Media Bias Ratings
Average Bias Rating:
Center
Center
byAd Fontes MediaCenter
byMedia Bias/Fact CheckDo you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top MedCity News News

National Institutes of Health · United StatesIn his confirmation hearings to lead the National Institutes of Health, Jay Bhattacharya pledged his openness to views that might conflict with his own. “Dissent,” he said, ”is the very essence of science.”See the Story
NIH scientists publish declaration criticizing Trump’s deep cuts in public health research
65% Center coverage: 162 sources

Merck · United StatesBy Jen Christensen, CNN (CNN) — The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants. The US Food and Drug Administration has approved a new monoclonal antibody to help prevent infection, according to an announcement late Monday from drugmaker Merck. Enflonsia is designed to be given in a single 105-milligram shot to protect newborns and i…See the Story
Newly Approved Antibody Could Offer Another Option for Protecting Infants From RSV, a Common Infection that Can Be Deadly
56% Center coverage: 32 sources

Europe · GermanyBioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins. The post BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute appeared first on MedCity News.See the Story
BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute
47% Center coverage: 28 sources
AstraZeneca Turns to CSPC Pharma Again, Putting Up $110M to Start Multi-Drug R&D Pact
100% Center coverage: 4 sources
Maximizing Equipment Uptime with Predictive Maintenance Technologies
100% Center coverage: 1 sources
Omada & Hinge’s IPO Debuts Signal Success for Digital Health Market, Experts Say
100% Center coverage: 1 sources
How to Meet the Digital Needs of Each Generation of Patients
100% Center coverage: 1 sources
Managing Routine Radiology: An Opportunity to Control Costs and Improve Care
100% Center coverage: 1 sources
Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer
100% Center coverage: 3 sources
Startup Launches to Help Women’s Health Providers Build Independent Practices
100% Center coverage: 1 sources